Recent studies have shown the efficacy and safety of IL-23 biologics for the treatment of moderate to severe plaque psoriasis. Think you know the ins and outs of IL-23 inhibitors? Test your knowledge with our Pop Quiz!
To read more about risankizumab, visit our Dermatology Advances resource.
Dr Andrew Blauvelt, a leading expert on novel dermatologic therapies, discussed the differences in maintenance of response and safety of various biologic therapies in an exclusive interview with The Dermatologist. Click the image below to watch the video!